Chronic treatment with benzodiazepines, which positively modulate c-aminobutyric acid A (GABA A ) receptors, can lead to the development of tolerance. Similar effects might also occur during chronic treatment with positive modulators acting at other sites on GABA A receptors (e.g. neuroactive steroids). In this study, tolerance and cross tolerance were examined in seven rats treated daily with the neuroactive steroid pregnanolone (25.6 mg/kg/day) and responding under a fixed ratio 10 schedule of food presentation. Dose-effect curves were determined for positive GABA A modulators (pregnanolone, flunitrazepam, midazolam, and pentobarbital), and other drugs (ketamine and morphine) before, during, and after chronic treatment. Initially, daily pregnanolone administration increased responding; although tolerance developed to the rate-increasing effects after 14 weeks, tolerance did not develop to the rate-decreasing effects. The potencies of pregnanolone, midazolam, and morphine to decrease responding did not change during treatment, whereas flunitrazepam was more potent and pentobarbital and ketamine were less potent during treatment as compared to before treatment. Pregnanolone and midazolam were more potent after treatment than before treatment. The development of tolerance to the rate-increasing effects of pregnanolone indicates that neuroadaptations occur during chronic treatment; the fact that tolerance develops to only some effects suggests that the behavioral consequences of these neuroadaptations are limited.
Introduction
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the mammalian nervous system and is involved in numerous processes, including development and organization of the central nervous system (Andang and Lendahl, 2008) , endocrine and neuroendocrine responses (Morrow et al., 1995; Cullinan et al., 2008) , and regulation of mood and anxiety states (Paul and Purdy, 1992; Smith et al., 2007) . Many effects of GABA are mediated by GABA A receptors, which are ligand-gated chloride channels that have several modulatory sites where benzodiazepines, barbiturates, and neuroactive steroids act. Positive modulation at these sites enhances the effects of GABA, thereby facilitating chloride conductance (Tallman and Gallager, 1985; Allan and Harris, 1986; Majewska et al., 1986) .
Positive GABA A modulators acting at benzodiazepine or barbiturate sites have long been used therapeutically in the treatment of anxiety, sleep disorders, and seizure disorders. Although benzodiazepines have a larger margin of safety than barbiturates, the use of these drugs can be limited by the development of tolerance and dependence, with benzodiazepine withdrawal symptoms ranging from uncomfortable (increased anxiety and insomnia) to potentially dangerous (seizures). Like benzodiazepines, drugs acting at the neuroactive steroid site, including pregnanolone, positively modulate GABA A receptors resulting in anxiolytic (Akwa et al., 1999) , sedative (Lancel et al., 1997) , and anticonvulsant (Kokate et al., 1998; Reddy and Rogawski, 2000a) effects. However, neuroactive steroids seem to differ from benzodiazepines in several important ways. One difference involves effects that occur when positive modulators are administered repeatedly, with tolerance developing to benzodiazepines under many different conditions (e.g. McMillan, 1992; Löscher et al., 1996; Gerak et al., 2008; Gerak, 2009 ) and developing to neuroactive steroids under a much more limited range of conditions. For example, tolerance to the anticonvulsant effects of benzodiazepines is readily apparent (Gonsalves and Gallagher, 1987; Löscher et al., 1996) , although tolerance does not develop to the anticonvulsant effects of pregnanolone (Kokate et al., 1998) or another neuroactive steroid, ganaxolone (Reddy and Rogawski, 2000b) . Such differences might provide a clinical advantage for neuroactive steroids as compared with benzodiazepines.
There are conditions under which tolerance can develop to neuroactive steroids, although it seems to be selective, with tolerance developing differentially depending on the particular neuroactive steroid studied or the dependent variable measured. For example, tolerance develops to the anesthetic (Zhu et al., 2004) and memory-impairing (Türkmen et al., 2006) effects of allopregnanolone and to the effects of minaxolone on locomotor activity (Marshall et al., 1997) , but not to the rate-decreasing effects of pregnanolone on schedule-controlled responding (McMahon and France, 2002a) . Direct comparisons between different neuroactive steroids are few, and the effects of chronic treatment must be compared across studies and dependent variables; however, one study examined the anesthetic effects of pregnanolone and allopregnanolone and found no evidence for acute tolerance to either neuroactive steroid (Zhu et al., 2001) . Altogether, these studies suggest that treatment with neuroactive steroids produces differential tolerance depending upon the treatment dose, species, dependent variable, or route, frequency or duration of administration.
This study systematically increased the dose and frequency of pregnanolone administered chronically to examine the development of tolerance to and dependence on a neuroactive steroid. To test whether tolerance developed, response rates and the potency of pregnanolone were compared before, during, and after chronic pregnanolone treatment. Cross-tolerance to positive GABA A modulators acting at other sites -the benzodiazepines midazolam and flunitrazepam, and the barbiturate pentobarbital -was examined by comparing potencies of modulators obtained during and after chronic pregnanolone treatment to their potencies obtained before chronic treatment. In addition, the N-methyl-Daspartic acid (NMDA) receptor antagonist ketamine and the m-opioid receptor agonist morphine were also studied before, during, and after chronic pregnanolone treatment. Another consequence of chronic treatment is the development of dependence, which is evidenced by the emergence of withdrawal when treatment is discontinued. In studies that did not find evidence of tolerance to neuroactive steroids, discontinuation of treatment resulted in an increased susceptibility to pentylenetetrazol-induced seizures (Reddy and Rogawski, 2000a ) and disruption in rates of food-maintained responding (McMahon and France, 2002a ), suggesting that dependence can develop during chronic neuroactive steroid treatment in the absence of tolerance. One reliable indicator of withdrawal is suppression of responding maintained by food presentation (Gellert and Sparber 1977; Ator et al., 2000; Ator and Griffiths, 2003) . To the extent that the current treatment conditions result in dependence, it would be indicated by disruptions in responding after temporary suspension of chronic pregnanolone treatment.
Methods

Subjects
Seven male Sprague-Dawley rats (Harlan, Indianapolis, Indiana, USA) weighing 250-300 g upon arrival were individually housed in a temperature-controlled and humidity-controlled vivarium on a 14-h light/10-h dark cycle. Weights were initially increased and then maintained at 320-330 g for the duration of the study by providing measured amounts of rodent chow daily (Harlan Teklad, Madison, Wisconsin, USA). Rats had free access to water in the home cage and grain-based pellets during experimental sessions (BioServ Inc., Frenchtown, New Jersey, USA). All experimental procedures were carried out under guidelines provided by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio and in accordance with the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, 1996) .
Apparatus and procedure
Experimental sessions were conducted daily at a specified time. White noise was used in the testing room to reduce extraneous noise. Standard operant boxes were contained in ventilated, sound-attenuating chambers (Med Associates, Inc., St Albans, Vermont, USA). The operant boxes (30 Â 24 Â 21 cm) were made of clear polycarbonate and aluminum. On one side of the box was a response panel with two levers, two stimulus lights, a pellet dispenser, and food cup. The floor of the box was made of stainless steel rods. During sessions, rats responded on one of the two levers under a fixed ratio 10 schedule of food presentation. Daily sessions consisted of two to eight 15-min cycles, each divided into a 10-min timeout, when responses had no programmed consequence, followed by a 5-min response period, during which time the stimulus light above the active lever was illuminated. Ten consecutive responses on the active lever resulted in the delivery of a single food pellet, with a maximum of 10 pellets delivered during each cycle. Responses on the inactive lever reset the count on the active lever to 0. Assignment of the left or right lever as the active lever was counterbalanced among rats. Stimulus lights were extinguished after 5 min or after the delivery of 10 food pellets, whichever occurred first. Any time remaining between delivery of 10 food pellets and the next cycle was a timeout. Data were collected using MED-PC IV software (Med Associates, Inc.).
During training sessions, vehicle or sham injections were given during the first minute of each cycle. Training continued until subjects satisfied the following testing criteria: response rates for each cycle were within ± 20% of the mean for that session and mean response rates for a single session were within ± 20% of the mean of 10 consecutive sessions, including the current one. Tests were conducted every third session as long as the testing criteria were satisfied during the intervening training sessions. If criteria were not met between tests, additional training sessions were conducted until testing criteria were satisfied for two consecutive sessions.
To determine the treatment dose of pregnanolone and the interval between pregnanolone administration and sessions, time course studies were conducted before chronic treatment, by giving pregnanolone on the first cycle, followed by seven sham cycles. Dose-effect curves were determined by administering vehicle on the first cycle followed by increasing doses of the test drug; injections were given during the first minute of each cycle. Cumulative doses increased in 0.25 or 0.50 log unit increments until response rates decreased to less than 10% of control rates. Dose-effect curves were determined for pregnanolone, flunitrazepam, midazolam, pentobarbital, ketamine, and morphine before chronic pregnanolone treatment.
Once dose-effect curves for all six drugs were determined, rats were treated daily with increasing doses of pregnanolone; an outline of the experimental design is presented in Table 1 . Chronic treatment continued for a total of 20 weeks. At the start of chronic treatment, rats received an injection of 5.6 mg/kg of pregnanolone in the home cage 1 h before sessions. As tolerance was not evident after 2 weeks of treatment with a single dose of pregnanolone, the frequency of dosing was increased to two daily injections of 5.6 mg/kg of pregnanolone (total dose: 11.2 mg/kg/day), given 5 and 1 h before sessions, for 5 weeks. Thereafter, a third daily injection of 5.6 mg/kg of pregnanolone was added 4 h after the second injection (approximately 2 h after sessions; total dose: 16.8 mg/kg/ day of pregnanolone); this treatment continued for 2 more weeks. Response rates and the potency of pregnanolone determined at this time indicated no development of tolerance; as a result, the treatment dose was further increased. For the remaining 11 weeks of treatment, one dose of 10.0 mg/kg of pregnanolone was given 5 h before sessions, a second dose of 5.6 mg/kg was given 1 h before sessions, and a third dose of 10.0 mg/kg was given 4 h after the second injection (total dose: 25.6 mg/ kg/day of pregnanolone). Throughout the study, doseeffect curves were determined twice weekly, beginning with a pregnanolone dose-effect curve on the fourth day of treatment and a flunitrazepam dose-effect curve on the seventh day of treatment. Thereafter, pregnanolone and flunitrazepam dose-effect curves were determined each week while treatment conditions were changing, with the exception of week 7 during which ketamine dose-effect curves were determined twice. The final treatment conditions were established by week 12. For the next 11 weeks, dose-effect curves for other drugs were determined when rats received pregnanolone before the session, so that the interval between the last pregnanolone injection and the session was 1 h. The third injection of pregnanolone was not given on testing days to avoid adverse effects. To test for the development of dependence, as measured by disruptions in rates of food-maintained responding, pregnanolone treatment was temporarily suspended for 25 h and rats received vehicle instead of pregnanolone for the three consecutive injections that preceded the session; vehicle was administered during the first cycle of sessions. On separate occasions, the vehicle cycle was followed by redetermination of dose-effect curves for each of the six drugs. For 2 weeks after the termination of chronic pregnanolone treatment, rats received three vehicle injections daily and dose-effect curves for pregnanolone and flunitrazepam were determined. Beginning four weeks after the termination of treatment, dose-effect curves for all drugs were redetermined.
Drugs
Pregnanolone (5b-pregnan-3a-ol-20-one; Steraloids, Inc., Newport, Rhode Island, USA) was dissolved in 45% (w/v) 2-hydroxypropyl-g-cyclodextrin (Sigma-Aldrich, St Louis, Missouri, USA). Sodium pentobarbital (Sigma-Aldrich) and morphine sulfate (Research Technology Branch, National Institute on Drug Abuse, Rockville, Maryland, USA) were dissolved in 0.9% saline. Ketamine hydrochloride (Fort Dodge Laboratories, Fort Dodge, Iowa, USA) and midazolam hydrochloride (Bedford Laboratories, Bedford, Ohio, USA) were purchased in solution and diluted in 0.9% saline. Flunitrazepam (Sigma-Aldrich) was dissolved in 20% emulphor, 10% ethanol, and 70% saline. All drugs were administered intraperitoneally.
Data analyses
Control response rates were determined for each rat before chronic treatment by first averaging the response rates across cycles within a training session, then across the 10 training sessions that immediately preceded the start of daily pregnanolone treatment. A paired t-test was used to determine changes in rates before and after chronic pregnanolone treatment. Time course data were analyzed by two-way repeated measures analysis of variance (ANOVA) using GraphPad 5.01 Software (San Diego, California, USA), with pregnanolone dose and time since injection as the factors. Significant ANOVAs were followed by Bonferroni's post-hoc test. A one-way repeated measures ANOVA was used to compare response rates on the first cycle (vehicle injection) of weekly test sessions before, during, and after treatment; post-hoc comparisons were made using Dunnett's Multiple Comparison Test to compare response rates on the first cycle of the session during and after treatment to response rates before treatment. Statistical tests were deemed significant when the P value was less than 0.05.
The dose of drug needed to decrease response rates to 50% of control rates (ED 50 ) was estimated by fitting straight lines to individual dose-response curves for each rat; each line was estimated using one dose that produced response rates at least 75% of control rates and one dose that produced response rates 25% or less of control rates and all doses in between. Potency ratios were calculated for each subject by dividing the ED 50 values during and after treatment by the ED 50 value before treatment, to determine changes in potency that might indicate the development of tolerance or cross tolerance during chronic treatment. Significant changes in potencies during and after treatment relative to before treatment were detected when the 95% confidence intervals of the potency ratios averaged across rats did not include 1.
Results
Control rates of responding
Before chronic treatment, mean control response rates varied across individual rats from 0.45 to 0.89 responses per second, with a group mean (± SEM) of 0.67 ± 0.06 responses per second. Rates of responding obtained 4 weeks after treatment (group mean: 0.64 ± 0.05 responses per second) were not significantly different from those obtained before treatment [t(6) = 0.79, not significant].
Time course studies
The rate-decreasing effects of a single, bolus dose of 5.6 mg/kg of pregnanolone were evident 15 min after administration ( Fig. 1) . A significant time Â dose interaction [F(21,120) = 4.11, P < 0.001] and a significant main effect of dose [F(3,120) = 26.97, P < 0.001] were detected. Bonferroni post-hoc tests revealed decreased response rates for 60 min after 5.6 mg/kg of pregnanolone; response rates were not different from control rates 75 min after administration. There was no significant change in rates of responding after administration of 1.0 (data not shown) or 3.2 mg/kg of pregnanolone compared with vehicle.
Daily treatment with pregnanolone
During chronic pregnanolone treatment, response rates on the first cycle of sessions were increased relative to response rates obtained on the first cycle of sessions before chronic treatment [F(16,119) = 6.85, P < 0.001]. This increase was evident on the first day of treatment, resulting in average response rates of 0.92 ± 0.07 responses per second. For 13 weeks, response rates on the first cycle of weekly test sessions were increased relative to rates obtained during the first cycle of the test session immediately before treatment began, regardless of daily pregnanolone dose (compare triangles and circles, Fig. 2) ; when pregnanolone treatment was suspended for 25 h before the session (squares, weeks 6 and 12, Fig. 2) , rates on the first cycle decreased and were no different from before treatment. Tolerance developed to the rateincreasing effects of pregnanolone by the fourteenth week of treatment. Thereafter, suspension of treatment for 25 h before sessions had no effect on response rates (square, week 18, Fig. 2) , and there was no change in rates 4 weeks after chronic pregnanolone treatment was terminated (diamonds, Fig. 2 ).
Dose-effect curves determined before treatment
Before chronic pregnanolone treatment, small doses of pregnanolone and midazolam increased rates of responding and larger doses had no effect or decreased rates (open circles, Fig. 3a and c) . The highest response rates occurred at a cumulative dose of 5.6 mg/kg of pregnanolone, which increased rates from 0.67 ± 0.06 under control conditions to 1.01 ± 0.05 responses per second. A dose of 0.1 mg/kg of midazolam increased responding to 0.90 ± 0.07 responses per second. Flunitrazepam, pentobarbital, ketamine, and morphine only decreased rates (open circles, Fig. 3b and d-f ).
Dose-effect curves determined during treatment
During chronic treatment, small doses of pregnanolone, flunitrazepam and midazolam increased rates of responding Selective tolerance to pregnanolone in rats Eppolito and Gerak 739 and larger doses had no effect or decreased rates (open triangles, Fig. 3a-c) . When pregnanolone treatment was suspended for 25 h, small doses of pregnanolone and flunitrazepam increased rates of responding and larger doses decreased rates (open squares, Fig. 3a and b ). Potency ratios with 95% confidence intervals for each drug and treatment condition are listed in Table 2 . During pregnanolone treatment, there was no change in the potencies of pregnanolone (Fig. 3a) , midazolam (Fig. 3c ), or morphine ( Fig. 3f ) to decrease response rates, as compared with their potencies before chronic treatment. The potency of flunitrazepam (Fig. 3b ) was increased during chronic pregnanolone treatment; there was a 3-fold shift leftward in the flunitrazepam dose-effect curve during treatment. Pentobarbital (Fig. 3d ) and ketamine (Fig. 3e ) were significantly less potent in decreasing response rates during chronic treatment; there was a significant 1.5-fold shift rightward in the pentobarbital dose-effect curve and a significant 5-fold shift rightward in the ketamine dose-effect curve. When pregnanolone treatment was suspended for 25 h, there was a significant 2-fold shift rightward in the midazolam dose-effect curve and a significant 3-fold shift rightward in the ketamine dose-effect curve. The potencies of pregnanolone, pentobarbital and morphine to decrease rates were unchanged when treatment was suspended for 25 h compared with before treatment. The potency of flunitrazepam was increased when pregnanolone treatment was suspended for 25 h, resulting in a 3-fold shift leftward in the flunitrazepam dose-effect curve.
Dose-effect curves determined after treatment
After chronic treatment, pregnanolone and midazolam were significantly more potent in decreasing response rates relative to before treatment, as indicated by 2-fold leftward shifts. The potencies of flunitrazepam, pentobarbital, ketamine, and morphine after treatment were not different from before treatment ( Table 2) .
Discussion
This study examined the development of tolerance and cross tolerance during chronic pregnanolone treatment. Daily treatment with pregnanolone increased responding for several weeks; however, by the fourteenth week of treatment, tolerance developed to the rate-increasing effects of pregnanolone and response rates were not different from rates before treatment. Larger doses of pregnanolone decreased responding; systematically increasing the daily treatment dose did not shift the ratedecreasing portion of the pregnanolone dose-effect curve rightward, indicating a lack of tolerance to the ratedecreasing effects of pregnanolone. When pregnanolone treatment was suspended for 25 h, rates of foodmaintained responding were not different from rates obtained before chronic treatment, regardless of whether tolerance had developed; that rates were not disrupted suggests that dependence did not develop.
Despite similarities in the acute behavioral effects (e.g. sedation and anticonvulsant effects) of positive GABA A modulators acting at different sites, the effects of chronic treatment with benzodiazepines or with neuroactive steroids seem to differ widely. Repeated treatment with benzodiazepines leads to the development of tolerance to anxiolytic (Fernandes et al., 1999) , sedative (McMillan, 1992) , and anticonvulsant effects (Izzo et al., 2001) in rats and mice. Tolerance also develops to the rate-decreasing effects of benzodiazepines under a variety of conditions (Cohen and Sanger, 1994; McMahon and France, 2002b; Gerak, 2009) . Although, under some conditions, sensitivity to neuroactive steroids decreases with repeated administration, the conditions under which tolerance develops to neuroactive steroids seem to be narrow. For example, tolerance develops to the memory-impairing (Türkmen et al., 2006) , anticonvulsant (Czlonkowska et al., 2001) and anesthetic effects (Zhu et al., 2004; Türkmen et al., 2008) of allopregnanolone; however, tolerance does not develop either to the effects of allopregnanolone on the components of sleep (Damianisch et al., 2001) or to the anticonvulsant effects of pregnanolone (Kokate et al., 1998) . In addition, strain differences have been noted in the development of tolerance to the hypothermic effects of allopregnanolone in mice selectively bred for high or lowsensitivity to ethanol-induced hypothermia (Palmer et al., 2002) . In the current study, tolerance developed to the rate-increasing effects of pregnanolone, but not to its ratedecreasing effects in this or another (McMahon and France, 2002a) study. Although some of the differences in the 
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week of chronic treatment. Vertical axis: response rates (± SEM) expressed as number of responses per second. development of tolerance to neuroactive steroids noted across studies might be because of the species studied, or route and duration of administration, these explanations cannot account for other inconsistencies, such as the differential development of tolerance observed in this study. Thus, decreased sensitivity to neuroactive steroids occurs under a limited set of conditions, possibly indicating an important difference between neuroactive steroids and benzodiazepines.
Following acute (Gerak et al., 2008) and chronic treatment (McMahon and France, 2002a) with benzodiazepines, cross tolerance to other benzodiazepines develops; however, cross tolerance does not develop to neuroactive steroids France, 2002a, 2002b; McMahon et al., 2007; Gerak et al., 2008; Gerak, 2009) . Although cross tolerance to benzodiazepines has been shown in subjects treated chronically with neuroactive steroids (McMahon and France, 2002a; Reddy and Rogawski, 2000b) , in this study, chronic pregnanolone treatment did not result in cross tolerance to benzodiazepines and produced a modest 1.5-fold shift to the right in the pentobarbital dose-effect curve. One possible explanation for differential development of cross tolerance is that During (1 h
) During (25 h) After
Cumulative dose-effect curves for pregnanolone (a), flunitrazepam (b), midazolam (c), pentobarbital (d), ketamine (e), and morphine (f) before (circles), during (triangles: pregnanolone last administered 1 h before session; squares: pregnanolone last administered 25 h before session), and after (diamonds) chronic pregnanolone treatment. During chronic treatment, dose-effect curves obtained when pregnanolone was last given 1 h before the session (triangles) were determined during week 11 for pregnanolone (a) and flunitrazepam (b) and during week 12 for midazolam (c) and ketamine (e), before tolerance developed to the rate-increasing effects of pregnanolone (points above vehicle); dose-effect curves for pentobarbital (d) and morphine (f) were determined during week 16 of treatment after tolerance developed to the rate-increasing effects of pregnanolone. Horizontal axis: cumulative dose in mg/kg body weight. Vertical axis: response rates expressed as number of responses per second. Gray shading indicates the 95% confidence intervals of control response rates before chronic treatment. See Table 2 for significant potency ratios.
Selective tolerance to pregnanolone in rats Eppolito and Gerak 741 the neuroadaptations that occur at GABA A receptors during chronic treatment differ depending on the site of action of the treatment drug. For example, in-vitro studies have shown that subunit composition of GABA A receptors is an important determinant of the affinity of positive modulators (Benke et al., 1996; Kohm et al., 2006; Baburin et al., 2008) . Chronic benzodiazepine treatment results in decreased benzodiazepine binding (Wu et al., 1994a) likely because of changes in the relative numbers of a1 and g2 subunits (Primus and Gallager, 1992; Wu et al., 1994b; Biggio et al., 2003) ; in contrast, chronic neuroactive steroid treatment alters expression of a4 mRNA (Smith et al., 2007) . Thus, the neuroadaptations of GABA A receptors during chronic benzodiazepine or neuroactive steroid treatment seem to differ. Changes in subunit composition during chronic pregnanolone treatment might also have differentially affected the potencies of the two benzodiazepines in this study. Whatever the reason for the lack of cross tolerance and the differential change in potencies of flunitrazepam and midazolam, differences in the development of cross tolerance between benzodiazepines and neuroactive steroids suggest that the mechanism by which tolerance develops varies across positive GABA A modulators.
When chronic benzodiazepine treatment is abruptly terminated, behavioral signs of withdrawal, such as increased anxiety, insomnia, muscle tremors, and seizures, are readily apparent (Woods et al., 1992; Ator and Griffiths, 2003) . Discontinuation of chronic benzodiazepine treatment can also disrupt operant responding for food (Ator et al., 2000) and is considered a sensitive measure of withdrawal, often noted in the absence of other physiological withdrawal signs (Emmett-Oglesby et al., 1990) . Given the similarities between benzodiazepines and neuroactive steroids administered acutely, including the ability of neuroactive steroids to reverse withdrawal in diazepam-dependent monkeys (McMahon et al., 2007) , it was expected that large doses of pregnanolone given repeatedly would result in the development of dependence and that withdrawal signs emerging after discontinuation of pregnanolone treatment would be similar to those that emerge after termination of chronic benzodiazepine treatment. Despite large doses given repeatedly, pregnanolone treatment failed to result in a disruption of food-maintained responding or any other overt behavioral signs of withdrawal, suggesting that, at least under these conditions, dependence does not develop to pregnanolone.
During pregnanolone treatment, sensitivity to ketamine decreased. There is evidence that NMDA receptors have distinct modulatory sites for neuroactive steroids (Park-Chung et al., 1997) , and these sites could play an important role in the changes in sensitivity to ketamine that were observed during chronic pregnanolone treatment. The decreased potency of ketamine during treatment might be due to compensatory changes occurring at NMDA receptors in response to enhanced GABAergic neurotransmission, as a result of daily pregnanolone treatment. Compensatory changes in the glutamatergic system are also evident during chronic benzodiazepine treatment (Izzo et al., 2001) . Changes in sensitivity to ketamine were temporary; 4 weeks after termination of daily pregnanolone treatment the potency of ketamine was no different from before treatment. The apparent cross tolerance to ketamine in addition to tolerance to the rate-increasing effects of pregnanolone provide evidence that complex interactions occur between the GABAergic and glutamatergic neurotransmitter systems during chronic pregnanolone treatment.
After chronic treatment, sensitivity to pregnanolone and midazolam was modestly increased suggesting that GABA A receptors were still changed long after daily pregnanolone treatment was terminated. It is known that changes in subunit composition of GABA A receptors can affect the functional properties of the receptor (Baburin , 2008) and that drug treatment can alter subunit expression (Yu et al., 1996) and coupling efficiency of the various binding sites on GABA A receptors (Yu and Ticku, 1995) , although it is not known which of the changes in GABA A receptors account for the development of tolerance to the rate-increasing effects of pregnanolone, or which changes persist after termination of treatment. Importantly, the potency of morphine, a drug that does not have actions at GABA A receptors, was unchanged by chronic pregnanolone treatment, further supporting the notion of selective changes at GABA A receptors.
In summary, daily treatment with pregnanolone resulted in selective tolerance to the rate-increasing, but not ratedecreasing effects of pregnanolone. Chronic pregnanolone treatment did not result in cross tolerance to the benzodiazepines flunitrazepam or midazolam, although cross tolerance to ketamine developed, and temporary suspension of treatment failed to result in any behavioral signs of withdrawal. Despite having similar modulatory actions at GABA A receptors, benzodiazepines and neuroactive steroids seem to differ in the development of tolerance and dependence, suggesting that neuroactive steroid modulatory sites might be effective therapeutic targets for the treatment of insomnia and seizure disorders while minimizing the unwanted effects that occur with repeated benzodiazepine use.
